Loading clinical trials...

COMPLETEDPHASE1

A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients With B-Cell Lymphomas

NCT02395601•Constellation Pharmaceuticals

Summary

First in human, open-label, sequential dose escalation and expansion study of CPI-1205 in patients with progressive B-cell lymphomas. CPI-1205 is a small molecule inhibitor of EZH2.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Adults (aged ≥ 18 years)
•Histologically confirmed diagnosis of a B-cell lymphoma that has progressed in spite of prior treatment, and for which additional effective standard therapy is not available
•Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
•Adequate hematological, renal, hepatic, and coagulation laboratory assessments
•Must give written informed consent to participate in this study before the performance of any study-related procedure

Exclusion Criteria

•A primary lymphoma of the central nervous system (CNS) or known lymphomatous involvement of the CNS
•Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of CPI-1205, including any unresolved nausea, vomiting, or diarrhea that is CTCAE grade \>1
•Treatment with proton pump inhibitors, H2 antagonists, or antacids
•Achlorhydria, either documented or suspected on the basis of an associated disease (e.g., pernicious anemia, atrophic gastritis, or certain gastric surgical procedures)
•Impaired cardiac function or clinically significant cardiac diseases, including any of the following:
•Acute myocardial infarction or angina pectoris ≤ 6 months prior to starting study drug
•New York Heart Association Class III or IV congestive heart failure
•QTcF \> 470 msec on the screening ECG
•Uncontrolled cardiac arrhythmia (patients with rate-controlled atrial fibrillation are not excluded)
•A past medical history of other clinically significant cardiovascular disease (e.g., uncontrolled hypertension, history of labile hypertension or history of poor compliance with an antihypertensive regimen)
+11 more criteria

Locations (6)

Horizon Oncology Center

Lafayette, Indiana, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

University of Nebraska Medical Center

Omaha, Nebraska, United States

John Theurer Cancer Center

Hackensack, New Jersey, United States

The Ohio State University James Cancer Hospital

Columbus, Ohio, United States

Sarah Cannon Research Institute

Nashville, Tennessee, United States

Key Dates

Start Date

March 1, 2015

Primary Completion Date

December 1, 2018

Completion Date

December 1, 2018

Last Updated

May 18, 2022

Enrollment

ESTIMATED participants

Conditions

B-Cell Lymphoma

Interventions

CPI-1205

DRUG

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

NCT05139017

DLBCLDiffuse Large B-Cell Lymphoma

View study

RECRUITINGPHASE1

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

NCT06026319

Non-hodgkin LymphomaRelapsed Non-Hodgkin Lymphoma+8 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 18, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas

Inclusion Criteria

Exclusion Criteria

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

A Long-term Extension Study of PCI-32765 (Ibrutinib)

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma